《新股》天岳先進(02631.HK)公開發售超購2,808倍 一手中籤率30%
天岳先進(02631.HK)公布招股結果,公開發售接獲2,809.19倍認購,一手(100股)中籤率30%,認購5萬股獲穩派一手。按回補機制,公開發售股份已增至1,671.1萬股,佔發售總數35%。國際發售錄得9.04倍認購。股份預期周三(20日)掛牌。
內地科創板上市半導體材料供應商天岳先進科技(688234.SH)是次擬全球發售4,774.57萬股H股,公開發售原佔5%。發售價42.8元,預計集資淨額19.38億元。五名基石投資國能環保投資集團、未來資產證券、山金資產管理、和而泰智能控制(002402.SZ)及個人投資者蘭坤合共認購1,729.52萬股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.